MedTrace Logo

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

NCT04556838 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2023-12-13

Study results available
· View outcomes & findings →

Summary

This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and tolerability and to explore the efficacy activity of VVN001 ophthalmic solution versus vehicle in subjects with dry eye disease.

Conditions

  • Dry Eye

Interventions

DRUG

VVN001 Ophthalmic Solution 1%

VVN001 Ophthalmic Solution 1%

DRUG

VVN001 Ophthalmic Solution 5%

VVN001 Ophthalmic Solution 5%

DRUG

Vehicle

VVN001 Ophthalmic Solution Vehicle

Sponsors & Collaborators

  • VivaVision Biotech, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-03
Primary Completion
2021-12-01
Completion
2021-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04556838 on ClinicalTrials.gov